Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Tony Keating
CEO & Managing Director, Tony Keating
Source: TechInvest Magazine
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medgate has begun a three-month pilot trial of ResApp Health’s (RAP) smartphone-based acute respiratory diagnostic test across its telemedicine services in Switzerland
  • ResAppDx is a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency departments and primary care settings
  • Both ResApp and Medgate will assess the impact of ResAppDx on Medgate’s telehealth service through a number of key performance indicators
  • The companies will enter into broader negotiations should the outcome of the trial be successful
  • ResApp is in the grey, last trading at 5.9 cents

Medgate’s three-month pilot trial of ResApp Health’s (RAP) smartphone-based acute respiratory diagnostic test has begun across its telemedicine services in Switzerland.

Medgate is a provider of telehealth services, operating the largest telemedical centre run by doctors in Europe since 2000.

During the integration process, ResApp and Medgate worked collaboratively to conduct clinical and technical reviews of the technology, known as ResAppDx.

ResAppDx is a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency departments and primary care settings.

“We are absolutely convinced that the use of new technologies like ResAppDx will enable an advancement of our digital health platform. This will benefit our patients by enabling them to be treated conclusively by phone or video in even more cases,” said Medgate CEO Dr Andy Fischer.

Testing of the technology included detailed mapping of user journeys for patients with respiratory disease symptoms, usability testing, the introduction of automated processes to enhance the patient experience, and the development of comprehensive training resources for clinical onboarding the maximise clinician confidence.

During the pilot, both ResApp and Medgate will assess the impact of ResAppDx on Medgate’s telehealth service through a number of key performance indicators.

“We are very confident that ResAppDx will provide considerable benefits for Medgate patients, physicians and insurers. Medgate has made a strong commitment to ResApp and both parties remain confident of a successful pilot trial,” said CEO and Managing Director Dr Tony Keating.

“The company has already significantly benefitted from Medgate’s knowledge and insights into telehealth best practice, and we look forward to continuing this work into the future”.

The companies will enter into broader negotiations should the outcome of the trial be successful.

ResApp is in the grey, last trading at 5.9 cents at 11:00 am AEDT.

RAP by the numbers
More From The Market Herald
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.

" Paragon Care (ASX:PGC) enters partnership with Centuria Healthcare for a healthcare facility

Paragon Care (PGC) has entered into a partnership with Centuria Healthcare for the 15-year lease of a state-of-the-art healthcare facility in Melbourne.